LOXL3 and central nervous system cancer: For instance, a previous study has demonstrated that the highest LOXL3 expression level is observed in the glioblastoma and genetic silencing of LOXL3 in U87 glioma cells has pronounced inhibition on invasive phenotype (Laurentino et al., 2021), which is a pivotal factor contributing to the recurrence and poor prognosis of GBM patients.